Characterisation of mexiletine’s translational therapeutic index for suppression of ischaemia-induced ventricular fibrillation in the rat isolated heart by Hesketh, Louise M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/s41598-020-65190-y
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Hesketh, L. M., Wilder, C. D. E., Ranadive, N. N., Lytra, G., Qazimi, P., Munro, J. S., ... Curtis, M. J. (2020).
Characterisation of mexiletine’s translational therapeutic index for suppression of ischaemia-induced ventricular
fibrillation in the rat isolated heart. Scientific Reports, 10(1), [8397 ]. https://doi.org/10.1038/s41598-020-65190-y
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Jul. 2020
1Scientific RepoRtS |         (2020) 10:8397  | https://doi.org/10.1038/s41598-020-65190-y
www.nature.com/scientificreports
characterisation of mexiletine’s 
translational therapeutic index for 
suppression of ischaemia-induced 
ventricular fibrillation in the rat 
isolated heart
Louise M. Hesketh, catherine D. e. Wilder, niraja n. Ranadive, Georgia Lytra, patrisia Qazimi, 
Jade S. Munro, nakita Ahdi & Michael J. curtis✉
the ‘translational therapeutic index’ (tti) is a drug’s ratio of nonclinical threshold dose (or 
concentration) for significant benefit versus threshold for adversity. In early nonclinical research, 
discovery and safety studies are normally undertaken separately. our aim was to evaluate a novel 
integrated approach for generating a tti for drugs intended for prevention of ischaemia-induced 
ventricular fibrillation (VF). We templated the current best available class 1b antiarrhythmic, 
mexiletine, using the rat Langendorff preparation. Mexiletine’s beneficial effects on the incidence of VF 
caused by 120 min regional ischaemia were contrasted with its concurrent adverse effects (on several 
variables) in the same hearts, to generate a TTI. Mexiletine 0.1 and 0.5 µM had no adverse effects, 
but did not reduce VF incidence. Mexiletine 1 µM reduced VF incidence to 0% but had adverse effects 
on atrioventricular conduction and ventricular repolarization. Separate studies undertaken using an 
intraventricular balloon revealed no detrimental effects of mexiletine (1 and 5 µM) on mechanical 
function, or any benefit against reperfusion-related dysfunction. Mexiletine’s TTI was found to be less 
than two, which accords with its clinical therapeutic index. Although non-cardiac adversity, identifiable 
from additional in vivo studies, may reduce the tti further, it cannot increase it. our experimental 
approach represents a useful early-stage integrated risk/benefit method that, when TTI is found to be 
low, would eliminate unsuitable class 1b drugs prior to next stage in vivo work, with mexiletine’s tti 
defining the gold standard that would need to be bettered.
Coronary heart disease and acute myocardial infarction (AMI) constitute the largest cause of death world-
wide1 with sudden cardiac death (SCD) responsible for approximately 50% of lethality2,3. Most SCD is due to 
ischaemia-induced arrhythmias, particularly ventricular fibrillation (VF) and ventricular tachycardia4.
Currently available antiarrhythmic drugs have failed against SCD5. The reason for this is that the benefit 
afforded by those drugs found to suppress SCD is offset by adverse drug reactions (ADRs); in some trials, mor-
tality was actually increased6–8 while in other trials attempts to minimise ADR risk by use of lower drug doses 
resulted in loss of effectiveness9,10.
Presently the class 1b antiarrhythmic, mexiletine, and the non-selective class III drug, amiodarone11, are the 
only antiarrhythmics prescribed for SCD outside the hospital setting, but even these drugs are not considered 
sufficiently efficacious for use in the larger lower-risk populations5,12 leaving a huge and longstanding unmet ther-
apeutic need4. Since amiodarone is an anomalous example of a class (III) that is otherwise discounted as a solu-
tion to SCD owing to proarrhythmia5,12, this leaves only class 1b agents as an avenue for new drug development.
An essential part of the process of any new drug development is to mitigate against ADRs during the nonclin-
ical phase. In view of this, we and others13 advocate better characterization of the ‘translational therapeutic index’ 
(TTI) in nonclinical models before first in human (FIH) studies are attempted. A TTI can be defined as the ratio 
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between the highest concentration without ADRs and the lowest concentration obtaining meaningful benefit, 
with a value of > 30 being deemed a minimum for most therapeutic scenarios14.
Our attempts to develop a new safer and more effective antiarrhythmic drug have recently focused on the 
testing of an ischaemia-selective class 1b drug, with preliminary data showing promise15. However, in order to 
gauge the potential advantage of this or any other new drug, we first need to formally define the gold standard: the 
template TTI of the best available current drug.
Mexiletine is prescribed for use against life-threatening ventricular arrhythmias5,16 with antiarrhythmic bene-
fit mediated by block of sodium currents within the ischaemic region and termination of re-entrant conduction17. 
In addition to its widely documented noncardiac ADRs18, mexiletine also has the capacity to adversely increase 
atrioventricular (AV) conduction time19–24. It can also elicit an adverse negative inotropic effect in vitro25,26, in 
vivo27,28, and in the clinical setting29,30, albeit negative inotropic effects are not dose limiting31–39.
Despite its limitations, mexiletine is the only orally-active class 1b antiarrhythmic to have had widespread 
clinical exposure, so its TTI in a nonclinical disease model would provide the necessary template to allow com-
parison, and evaluation of the potential value, of any novel class 1b agent, by setting the height of the bar that any 
new drug must reach in order for it to become a candidate for translation.
A TTI in nonclinical research can be hard to obtain and harder to interpret owing to the multiplicity of experi-
ments and models that may be used to generate different types of data (e.g., concentration-dependence of channel 
block, receptor affinity, pharmacokinetic data, and dose-dependence of effectiveness in a disease model) con-
stituting the nonclinical portfolio. However, these obstacles diminish if readout for benefit and adversity are 
obtained at the same time using a single preparation (contiguously). If, in addition, studies are undertaken in 
vitro or ex vivo, complications associated with steady state drug concentration (affected by drug metabolism and 
distribution and plasma protein binding) can be disregarded and the TTI can be defined in terms of drug con-
centration rather than dose13.
Thus, in the present study we have characterized the TTI of mexiletine in the rat isolated heart, a standardized 
bioassay for detecting beneficial drug effects on ischaemia-induced VF40 and cardiac ADRs. The latter are mani-
fest and defined as any effect on heart rate, coronary flow, intervals in the electrocardiogram (ECG), or ventricular 
mechanical function before the onset of, or during, ischaemia.
Using this integrated approach, we found that suppression of ischaemia-induced VF could not be obtained 
at any concentration devoid of one or more ADR. Given this, and the evidence that noncardiac ADRs are the 
threshold ADRs for mexiletine in vivo in humans31,34,35,37–39, it is evident that mexiletine has an unfeasibly narrow 
therapeutic window for suppression of ischaemia-induced VF (TTI < 2). We propose that, in future research, 
one may use the present data set as a template with which to gauge the potential value of new drugs, using an 
equivalent protocol.
Methods
Arrive, ethical, legal and experimental requirements. Animal housing and husbandry were as previ-
ously described41 and in compliance with ARRIVE42, the UK Home Office Guide on the Operation of the Animals 
(Scientific Procedures) Act 1986, and appropriate guidance on experimental design and analysis43,44. All exper-
iments were performed under project licence PPL 70/7491 at King’s College London, and were approved by the 
King’s College London Animal Welfare and Ethical Review Board.
Animals and general experimental methods and materials. Rats were chosen for studies because 
they have a coronary anatomy that lends itself to generation of reproducible susceptibility to ischaemia-induced 
VF that is well characterised, and the in vitro (Langendorff perfusion) variation lends itself to the tractable evalu-
ation of the concentration-dependence of the effects of drugs on VF and other variables40. Male Wistar rats (254–
475 g) were anaesthetised with a lethal dose of sodium pentobarbitone (170 mg.kg−1) and heparin (160 IU.kg−1) 
via intraperitoneal (i.p.) injection to achieve a surgical level of anaesthesia, confirmed by removal of pedal and 
corneal reflexes. Hearts were then excised (causing death by exsanguination) and immediately submerged in cold 
(4 °C) Krebs solution containing NaCl 118.5 mM, CaCl2 1.4 mM, glucose 11.1 mM, NaHCO3 25.0 mM, MgSO4 
1.2 mM, NaH2PO4 1.2 mM and KCl 3 mM. Hearts were then cannulated via the aorta for Langendorff perfusion 
via the coronary arteries, and perfused with Krebs (as above), filtered (5μm pore size), warmed to 37 °C and gassed 
with 95% O2 and 5% CO2 to achieve a pH of 7.4, at a constant pressure of approximately 80 mmHg. Mexiletine 
(Sigma-Aldrich, UK) stock solutions were made up in a vehicle of 1:4, Ethanol (VWR International, UK): Water 
(PURELAB ELGA Process Water, UK). Krebs perfusate salts were purchased from VWR International, UK.
coronary artery ligation. A unipolar electrode was inserted in the apex of the heart, connected to a 
PowerLab (ADInstruments, UK), and used to detect heart rate and rhythm, with arrhythmias defined, detected 
and analysed according to guidance from The Lambeth Conventions44. A silk suture (4-0) was sewn around the 
left anterior descending (LAD) coronary artery, 1-2 mm below the left atrial appendage towards the apex, and 
threading both ends of the suture through a polythene tube. The suture was later tightened with and clamped 
(using forceps) to occlude the LAD coronary artery, inducing regional ischaemia, and subsequently loosened 
to reperfuse the artery. Following completion of the experimental protocol, the involved zone (IZ) size, defined 
as the anatomical region of myocardium that had been subjected to ischaemia, was identified by re-occlusion 
during perfusion with 5% disulphine blue dye (Patent blue VF sodium salt, Sigma-Aldrich, UK), dissected and 
quantified as % of total ventricular weight (TVW). An IZ size of 40-60% TVW was expected given the chosen 
suture positioning45.
experimental design and protocol. Mexiletine concentrations were chosen to span values slightly below 
and above reported clinically effective free plasma concentrations for suppression of ventricular arrhythmias46,47. 
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Three concentrations of were examined: 0.1 μM, 0.5 μM and 1 μM (n = 18/group), all of which were compared 
with a matched vehicle control group (3 x n = 18). Initially, 1 µM was examined in the expectation this would 
suppress VF but possess ADRs. Once this was confirmed, the lower concentrations of mexiletine were studied 
in order to reveal at what concentration VF suppression could be achieved without ADRs. This experimental 
design was implemented to minimise animal usage. All experiments were blinded and randomised and followed 
a defined protocol.
Following a 5 minute period of Krebs perfusion, measurements of heart rate (beats.min−1), coronary flow (ml.
min−1.g−1), PR interval and QT90 (QT interval at 90% repolarisation) interval times (msec) were begun, repeated 
at specified time points during the protocol. Perfusate was then switched to a test solution or control. After a fur-
ther 5 minutes, regional ischaemia was induced for 120 minutes, followed by reperfusion for 10 minutes, and then 
IZ size delineation. In a subset of the hearts perfused with 1 μM mexiletine (n = 9) a higher K+ concentration of 
5 mM K+ was introduced at the 90th minute of ischaemia, with mexiletine or control solution continued for the 
remainder of the protocol, to examine whether any antiarrhythmic or adverse effects of mexiletine were depend-
ent on ambient K+ in the heart, a factor examined previously and found to influence outcome in studies with 
other class I (and class IV) antiarrhythmics48–50. The 120 minute length of ischaemia was also chosen to capture 
beyond the scope of the full spectrum of phase 1 ischaemia-induced ventricular arrhythmias in the rat isolated 
heart, which arise and then dissipate during the first 90 minutes of regional ischaemia51,52. The occurrence of VF 
during the first 90 minutes of ischaemia was presented and analysed separately from VF occurring later because 
there is a possibility that mechanisms of VF differ between early and more sustained ischaemia, and the actions 
of drugs diminished, exacerbated or even converted from protective to proarrhythmic51,53. Our protocol was 
designed to explore all these possibilities without adding unnecessary extra groups (minimising animal usage).
Coronary flow and ECG analysis. Coronary flow (ml.min−1.g−1) was measured by timed collection of 
effluent, which was weighed (1 g = 1 ml), and then expressed relative to the TVW of the respective heart. ECG 
and pressure measures such as heart rate (beats.min−1), PR and QT90 intervals (msec), diastolic and developed 
pressures (mmHg) were obtained only during sinus rhythm. Ventricular arrhythmias defined according to the 
Lambeth Conventions II44 were recorded as ‘present’ or ‘absent’ within sequential 30-minute time periods during 
ischaemia, and the during first 10 minute period of reperfusion.
exclusion criteria. Any heart that, prior to switch to test solution, had a coronary flow that fell outside the 
range of 7 to 20 ml.min−1.g−1, a sinus heart rate of less than 200 beats.min−1, or an IZ size less than 40% TVW was 
excluded from the study, and subsequently replaced to maintain equal group sizes while maintaining blinding41. 
Hearts that met exclusion criteria were not excluded if doing so would not affect the outcome of the study (i.e. if 
VF occurred despite the IZ being below the size criterion, which is used to ensure that if VF did not occur in an 
individual heart, it was not due to IZ being ‘too small for VF to occur’54).
Supplementary studies assessing left ventricular contractile function. Evaluation of left ventricu-
lar function was undertaken using Krebs modified to contain 4 mM KCl in an experiment undertaken separately 
from the arrhythmia study, owing to technical reasons recently identified55. A deflated intraventricular balloon 
(IVB), made from complaint non-elastic material, attached to a pressure transducer was inserted into the left 
ventricle via the left atrium for assessment of two components of contractile function, namely diastolic function 
as defined by diastolic pressure, and inotropy as defined by developed pressure (the difference between peak sys-
tolic pressure and minimum diastolic pressure during a single cardiac cycle during sinus rhythm). Once attached 
to the perfusion apparatus, hearts were submerged in coronary effluent contained within a heated jacket (37 °C) 
to preclude a fall in temperature, later, during global ischaemia. The IVB was filled with a small volume of saline 
(~0.02 ml) so that a pressure could just be measured, and the arbitrary value on the syringe noted as the ‘zero 
volume’. Using the zero volume as a reference point the syringe was then filled with a volume of saline (typically 
~0.12 ml for a 0.7–0.9 g heart) sufficient to generate a developed pressure >100 mmHg, without elevating diastolic 
pressure to >10 mmHg (avoiding excessive diastolic stretch). This volume was defined as the ‘working volume’ 
and was set when examining effects of solution switching and effects of ischaemia and reperfusion. After cessation 
of each protocol, the hearts were removed from the Langendorff set up, the atria and any extra-cardiac tissue was 
removed, and the TVW (g) was measured.
Experimental design and protocol. Mexiletine was evaluated at up to 5 μM on the expectation based on clini-
cal reports that adverse effects on contractile function would require a higher concentration than that evoking 
adverse effects on the ECG38. Each group was compared with a vehicle control group (all n = 9). Following a 
5 minute period of Krebs perfusion, measurements of heart rate (beats.min−1), coronary flow (ml.min−1.g−1), 
ventricular diastolic pressure (mmHg) and developed pressure (mmHg) were taken at various predetermined 
time points. A Starling curve was constructed by deflating the IVB to zero volume before inflating the IVB with 
0.02 ml increments of saline (up to a diastolic pressure <20 mmHg) and recording the incremental changes in 
diastolic and developed pressure (mmHg). Perfusate was then switched to one of the three test solutions and 
5 minutes later a second Starling curve was constructed. Global ischaemia was then induced by clamping the 
tubing above the aortic cannula, maintained for 20 minutes. Reperfusion was initiated by releasing the clamp, 
using the same test solution, and maintained for 60 minutes, whence a third Starling curve was constructed to 
determine drug effects on recovery of mechanical function.
Data and statistical analysis. Selection of group sizes was based on previous experience with the models 
used40, and an expectation that assessment of threshold concentrations achieving effects (i.e., detection of weak 
drug effects) would require larger group sizes than normal for establishing statistical significance, as found in 
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previous studies41. Studies were undertaken using randomization followed by blinded analysis44 and in accord-
ance with BJP’s guidance in terms of group sizes, normalizations (none used) and Y axis labelling (all raw var-
iables and no ‘fold control’)43. Statistical analysis was undertaken to determine whether individual test groups 
differed from drug-free controls. Gaussian distributed variables were subjected to an unpaired t test (when there 
were only two groups) or to ANOVA (1 way or 2 way, repeated measures when appropriate) when more than 
two groups were contrasted. After ANOVA, if F was significant and no variance inhomogeneity was detected, 
Dunnett’s post hoc test was used to identify the groups in which variables had changed compared with con-
trols. All Gaussian-distributed values were expressed as mean ± SEM since representation of raw data values or 
standard deviations renders many data sets impossible to fathom due to clutter. Binomially distributed variables 
were compared using Fisher’s exact tests. The threshold P value denoting statistical significance was P < 0.05. 
Differences between groups are described as effects or changes always and only when statistically significant. 
Statistical analysis was performed in GraphPad prism 7 (UK) software.
ethical approval. All applicable international, national, and/or institutional guidelines for the care and use 
of animals were followed.
Declaration of transparency and scientific rigour. This paper adheres to the principles for transparent 
reporting and scientific rigour of nonclinical research recommended by funding agencies, publishers and other 
organisations involved with supporting this research.
Results
Design validation. IZ size was similar in each group (Fig. 1A–C), validating the effectiveness of randomisa-
tion in fulfilling the requirement for parity of arrhythmogenic stimulus54.
Concentration-dependence of effect of mexiletine on ischaemia-induced VF. The inci-
dence of VF was approximately 50% in controls, providing scope for detection of inhibition by mexiletine 
(Fig. 2A–C). Mexiletine had no effect on VF at 0.1 and 0.5 µM whereas 1 µM abolished it, indicating a steep 
concentration-dependence (Fig. 2A–C). Representative ECG traces of sinus rhythm, ischaemia-induced VT and 
ischaemia-induced VF are displayed in Fig. 2D.
ADRs. Recorded variables in control hearts followed the pattern typical for the preparation51,55–57, with heart 
rate and coronary flow falling slightly during ischaemia, and then recovering during reperfusion, PR intervals 
varying little over time, and QT intervals increasing during ischaemia and decreasing during reperfusion (Fig. 3, 
4 and 5A–D). Neither 0.1 nor 0.5 µM mexiletine had any effect on any variable (Fig. 3A–D). 1 µM mexiletine did 
not affect coronary flow (Fig. 5B), or heart rate versus control (Fig. 5A), but it did prolong the PR interval and 
QT interval with effects beginning before the onset of ischaemia (Fig. 5C,D), indicating off-target pharmacology 
in non-ischaemic supraventricular and ventricular tissue. The introduction of 5 mM K+ at the 90th minute of 
ischaemia did not alter these effects.
Effects of mexiletine on left ventricular contractile function. Mexiletine, tested only at the higher 
two concentrations (1 µM and 5 µM), had no effect on heart rate or coronary flow (Fig. 6A,B), replicating findings 
(above) from hearts not fitted with an IVB. Prior to ischaemia, neither concentration of mexiletine affected dias-
tolic or systolic pressure at the IVB’s working volume (Fig. 6C,D). In all groups, diastolic pressure was increased, 
and developed pressure was decreased during 60 min reperfusion following global ischaemia with the partial 
recovery of function during reperfusion not altered by 1 or 5 µM mexiletine (Fig. 6C,D).
Figure 1. Involved Zone Size (% TVW) resulting from proximal ligation of the left coronary artery in rat 
isolated hearts perfused with (A) 0.1 µM mexiletine, (B) 0.5 µM mexiletine and (C) 1 µM mexiletine, measured 
as % total ventricular weight (TVW) each compared with separate groups of matched control hearts, n = 18 per 
group, mean ± SEM. There were no statistically significant differences between groups.
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Consistent with these findings, Starling curve analysis revealed that neither 1 µM nor 5 µM mexiletine had any 
discernible effect on either systolic or diastolic function prior to ischaemia, or during reperfusion, with the slope 
of each volume:pressure line indistinguishable from control throughout the protocol (Fig. 7A–F).
Discussion
Mexiletine and the need for quantitative nonclinical therapeutic window data. Among the few 
drugs used to treat severe life-threatening ventricular arrhythmias during, or following, AMI5,58 mexiletine is the 
archetypal orally-active class 1b antiarrhythmic11. It is the only clinically used antiarrhythmic for prevention of 
SCD that represents an archetype that may serve as a gold standard, since the only other drug for this indication, 
amiodarone, is anomalous within its nominal class5, and not an archetype that may serve as a focus for novel drug 
development. Clinically effective plasma mexiletine concentrations that provide antiarrhythmic benefit without 
treatment-terminating ADRs are reported to be 0.5-2.0 µg/ml46,47. To achieve this, an oral dose of 200-300 mg 
every 8 hours is required [16]. However, the plasma concentration range of a drug encountered therapeutically 
is often wider than the therapeutic window13. The average plasma concentration of mexiletine causing ADRs is 
0.88 µg/ml, and the threshold concentration triggering treatment withdrawal is approximately 0.95 µg/ml38. The 
clinical therapeutic window is thus concerningly narrow. Unsurprisingly therefore, although initial clinical trials 
reported positive findings31–35,37,39,59 mexiletine has not emerged as a drug for primary prevention of SCD12; as 
with all antiarrhythmics its ADRs are perceived to outweigh benefit in this context5,16. Consequently, since this, 
the most useful drug has limited utility, there remains an important unmet clinical need for primary prevention.
In mexiletine’s nonclinical development phase it would have been useful to have had a clear characterization of 
the doses and concentrations obtaining safe antiarrhythmic activity. Currently, for a drug to be viable for advance-
ment to therapeutic evaluation in humans it must have a an adequate TTI13, and the drug with the best TTI would 
serve as a template with which to judge developing drugs. Unfortunately, although mexiletine was examined for 
antiarrhythmic activity in a variety of animal models in vitro60, ex vivo61,62 and in vivo27,63–66, no systematic attempt 
was made to determine its TTI. The aim of the present study was to rectify this, using the highly tractable rat 
Langendorff isolated perfused heart model and, in doing so, exemplify the model/approach and provide a mexile-
tine data set for use as a template with which to evaluate whether novel, as yet, untested drugs offer an advantage.
Figure 2. Incidence of Ventricular Fibrillation (% of total hearts per group) during 120 min of regional 
ischaemia, and (separately) during 10 min reperfusion, for rat hearts perfused with or without (A) 0.1 µM 
mexiletine, (B) 0.5 µM mexiletine and (C) 1 µM mexiletine (here, in half of the hearts, the K+ in the solution was 
changed 30 min before the start of reperfusion to 5 mM with all other constituents including drug concentration 
unchanged), n = 18 per group, and n = 9 (for the last 30 min of ischaemia and 10 min reperfusion). *P < 0.05 
versus control. (D) Representative ECG traces displaying sinus rhythm, ischaemia-induced VT and ischaemia-
induced VF during first 30 mins of regional ischaemia.
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Principal findings and implications. We found that 0.1 µM and 0.5 µM mexiletine did not exhibit antiar-
rhythmic effects. Unsurprisingly, these concentrations are lower than those (in plasma) reported to provide clin-
ical effectiveness46,47. A doubling of concentration to 1 µM was effective against VF. However this concentration 
precipitated ADRs, causing prolongation of the PR and QT intervals, just as a doubling of plasma concentration 
Figure 3. Haemodynamic and ECG changes in rat hearts perfused with or without 0.1 µM mexiletine during 
120 minutes left coronary artery ligation and 10 minutes reperfusion. (A) Heart rate (beats.min−1), (B) 
Coronary flow (ml.min−1.g−1), (C) PR interval (msec), (D) QT90 interval (msec). n = 18 per group; mean ± 
SEM. *P < 0.05 versus time-matched vehicle control. There were no statistically significant differences between 
groups for any variable.
Figure 4. Haemodynamic and ECG changes in rat hearts perfused with or without 0.5 µM mexiletine during 
120 min left coronary artery ligation and 10 min reperfusion. (A) Heart rate (beats.min−1), (B) Coronary flow 
(ml.min−1.g−1), (C) PR Interval (msec), (D) QT90 Interval (msec). n = 18 per group, mean ± SEM. *P < 0.05 
versus time-matched vehicle control. There were no statistically significant differences between groups for any 
variable.
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to 1 µg/ml results in serious ADRs in humans38, and subtherapeutic doses of mexiletine in a conscious rat model 
of ischaemia-induced VF caused an unacceptable reduction in blood pressure67. These results indicate that the 
consensus therapeutic index for mexiletine in humans (based on disparate data) was replicated by the TTI in 
Figure 5. Haemodynamic and ECG changes in rat hearts perfused with or without 1 µM mexiletine during 
120 min left coronary artery ligation and 10 min reperfusion. Here, in half of the hearts, the K+ in the solution 
was changed 30 min before the start of reperfusion to 5 mM with all other constituents including drug 
concentration unchanged, n = 18 per group, and n = 9 for the last 30 min of ischaemia and 10 min reperfusion. 
(A) Heart rate (beats.min−1), (B) Coronary flow (ml.min−1.g−1), (C) PR Interval (msec), (D) QT90 Interval 
(msec). Values are mean ± SEM. *P < 0.05 mexiletine versus time-matched vehicle control, #P < 0.05 mexiletine 
+ high K+ versus time-matched high K+ vehicle control.
Figure 6. Haemodynamic and ECG changes during 20 min global ischaemia and 60 min reperfusion in rat 
hearts perfused with or without 1 µM mexiletine or 5 µM mexiletine. (A) Heart rate (beats.min−1), (B) coronary 
flow (ml.min−1.g−1), (C) diastolic pressure (mmHg) and (D) developed pressure (mmHg). All n = 9 per group, 
mean ± SEM. *P < 0.05 versus time-matched vehicle control. There were no statistically significant differences 
between groups for any variable.
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the rat Langendorff preparation, and was confirmed to be impracticably small, requiring a concentration above 
0.5 µM yet below 1 µM - a TTI of less than two. This is clearly insufficient to meet the 30-fold criteria typically 
predictive of a safe, effective drug14.
Overall these findings validate the experimental approach elaborated in the present study and explain the 
limited clinical utility of mexiletine.
Study strengths and limitations. The Langendorff-perfused rat heart has been used extensively for eval-
uating drug-induced effects on ischaemia-induced VF, and is highly tractable40. Additionally, it provides scope 
for identifying drug-induced ADRs for numerous drug classes including those that block cardiac sodium current 
(INa) and cardiac and vascular L-type calcium current (ICaL)40,49,50,53,57,68 albeit not delayed rectifying potassium 
current blockers40. In addition to detection of ECG effects, increases in coronary flow in the perfused rat heart50,69 
are predictive of peripheral vasodilatation and clinical hypotensive effects70. The present approach therefore 
allows early identification of a new drug as unviable owing to dose limiting cardiac ADRs. However, an isolated 
perfused heart self-evidently cannot be used to assess noncardiac ADR risk.
Concern about possible noncardiac ADRs would arise if a drug were found to have a TTI in the rat isolated 
heart that is sufficiently large to justify further nonclinical development (i.e., >30), and noncardiac ADRs would 
then be examined by other means. The advantage of our approach, however, is that any drug with cardiac ADRs 
will have been excluded from further development. Thus, although mexiletine can cause central nervous system 
toxicity and gastrointestinal discomfort at plasma concentrations lower than those causing ADRs related to the 
ECG31,34,35,37–39,71, its small TTI in the rat isolated heart renders its extracardiac ADRs irrelevant. For any new class 
1 antiarrhythmic, a TTI of >30 would need to be met using our protocol, and only then would examination of its 
noncardiac ADRs be justified; reducing animal usage is an added benefit.
The rat heart has numerous advantages for TTI assessment of putative anti-VF drugs that are well docu-
mented, including an ability to manifest a reproducible susceptibility to ischaemia-induced VF40, but some hypo-
thetical reasons for concern about this species choice remain. Class 1 drug-induced ventricular or AV nodal 
conduction abnormalities may occur to a greater extent, or at a lower drug concentration, in species such as the 
rat that has a basal heart rate higher than that of humans, if the drug’s effects on INa are characterized by slow 
binding and unbinding rates, typical of class 1c and 1a drugs72. However, this would not be a concern for drugs 
that bind and unbind from sodium channels quickly, such as mexiletine and other 1b drugs72. The present data 
accord with this since mexiletine’s TTI in the rat heart mapped to the human therapeutic index. The predictive 
value of the rat heart may not be optimal for class 1c or 1a drugs, but these drugs are no longer used for treating 
Figure 7. Changes in Diastolic pressure (mmHg) and Developed pressure (mmHg) generated from Starling 
curves in the rat Langendorff preparation, with or without 1 µM mexiletine and 5 µM mexiletine performed 
during Krebs perfusion (A,D), after switch to 1 µM mexiletine, 5 µM mexiletine or vehicle (B,E) and following 
20 min global ischaemia and 60 min reperfusion (C,F). The slope of diastolic or developed pressure (mmHg) 
and IVB volume (ml) was analysed by linear regression analysis. All n = 9 per group, mean ± SEM. There were 
no statistically significant differences between groups for any variable.
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ventricular arrhythmias, so the need to test a novel 1c or 1a drug in any nonclinical model of SCD and VF is 
unlikely to arise.
conclusions. Nonclinical data sets can be complex with a variety of estimates of affinity and potency for 
actions on a range of different molecular targets and tissues. Additionally, safety and effectiveness are rarely inves-
tigated in tandem. This makes it difficult to obtain an estimate of a TTI. For a decision to be made on the likely 
clinical success and safety of a new antiarrhythmic, the nonclinical database must be sufficiently accurate to 
mitigate against false inference. In the SCD therapeutic area, failed translation has become the rule rather than 
the exception, with development blighted by low effectiveness coupled with ADRs at therapeutic dosage6–10. This 
requires better early-stage elaboration of the TTI using simple tractable approaches.
The integrated evaluation of safety and effectiveness (exemplified in the present study) aims to reduce animal 
requirements by effectively halving the number needed to estimate the TTI if effectiveness and safety were evalu-
ated independently. The rat Langendorff preparation was shown to detect cardiac ADRs contiguously with ben-
eficial effects on ischaemia-induced VF with a TTI (<2) that replicates the consensus clinical therapeutic index. 
The experimental approach outlined was therefore validated and provides a template ‘gold standard’ for future 
early nonclinical assessment of novel antiarrhythmics, particularly antiarrhythmics with class 1b characteristics, 
the one remaining class that is not intrinsically flawed owing to insurmountable ADRs including proarrhythmia 
related to its primary molecular pharmacology in the heart.
Finally, it is important to clarify the context of the present work. If a novel drug (class 1b, certainly, or drug of 
novel class), were to be found to have a promising therapeutic index in the rat Langendorff preparation this would 
allow its development to proceed, and if the drug were later found to have dose-limiting noncardiac adversity this 
will be detected by other means, for example when the efficacy and safety are examined using an in vivo animal 
model. Species with a lower basal heart rate than the rat, such as the dog73 are not suitable for early nonclinical 
evaluation owing to costs and ethical considerations. Our suggestion would be to utilise the Langendorff-perfused 
rat heart model to benchmark the TTI of a class 1b agent and verify findings in vivo, and then in a second species, 
only if justified at each stage of experimentation (TTI > 30-fold). Class 1b drugs that do have dose-limiting car-
diac ADRs that give rise to a narrow TTI will be detected in the rat Langendorff preparation, and rejected, saving 
the animals, time and cost that would have been expended exploring the drug’s ADRs by other means.
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